0R15 8760.0 -2.9363% 0R1E 9131.0 -2.9649% 0M69 None None% 0R2V 255.95 6.4241% 0QYR 1588.0 1.3078% 0QYP 439.59 -0.2066% 0RUK None None% 0RYA 1530.0 -4.1954% 0RIH 190.8 0.0% 0RIH 193.71 1.5252% 0R1O 226.72 9954.102% 0R1O None None% 0QFP None None% 0M2Z 255.4879 -0.0829% 0VSO 33.09 -7.0636% 0R1I None None% 0QZI 599.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 227.3 2.2952%
Last update at 2024-12-23T09:37:00Z
With 63% institutional ownership, Bioventix PLC (LON:BVXP) is a favorite amongst the big guns
Sat 05 Aug 23, 08:47 AMInvestors in Bioventix (LON:BVXP) have seen respectable returns of 76% over the past five years
Wed 10 May 23, 05:12 AMHolding your investment in this antibody manufacturer could provide a real shot in the arm
Fri 21 Apr 23, 05:00 AMDo Bioventix's (LON:BVXP) Earnings Warrant Your Attention?
Wed 19 Apr 23, 11:33 AMBioventix (LON:BVXP) Is Paying Out A Larger Dividend Than Last Year
Thu 30 Mar 23, 05:06 AMBioventix PLC's (LON:BVXP) Stock Is Going Strong: Is the Market Following Fundamentals?
Fri 20 Jan 23, 09:36 AMEstimating The Intrinsic Value Of Bioventix PLC (LON:BVXP)
Fri 16 Dec 22, 10:44 AMWe Discuss Why Bioventix PLC's (LON:BVXP) CEO May Deserve A Higher Pay Packet
Fri 02 Dec 22, 05:03 AMBioventix (LON:BVXP) shareholders have earned a 12% CAGR over the last five years
Fri 18 Nov 22, 08:25 AM| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | 10.13M | 9.28M | 8.12M | 8.23M | 6.97M |
| Minority interest | - | - | - | - | - |
| Net income | 8.37M | 7.67M | 6.73M | 7.20M | 5.86M |
| Selling general administrative | 1.77M | 1.61M | 1.51M | 1.42M | 1.27M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 11.99M | 11.01M | 10.11M | 9.49M | 8.41M |
| Reconciled depreciation | 0.13M | 0.14M | 0.14M | 0.13M | 0.07M |
| Ebit | 10.13M | 9.28M | 8.38M | 7.98M | 6.93M |
| Ebitda | 10.26M | 9.42M | 8.52M | 8.11M | 7.03M |
| Depreciation and amortization | 0.13M | 0.14M | 0.14M | 0.13M | 0.10M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 10.03M | 9.27M | 8.09M | 8.18M | 6.93M |
| Other operating expenses | 2.75M | 2.54M | 2.55M | 2.33M | 2.26M |
| Interest expense | 0.00000M | 0.00030M | 0.26M | 0.24M | 0.00000M |
| Tax provision | 1.76M | 1.60M | 1.39M | 1.02M | 1.10M |
| Interest income | 0.10M | 0.00480M | 0.03M | 0.04M | 0.03M |
| Net interest income | 0.10M | 0.00450M | 0.03M | 0.04M | 0.03M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1.76M | 1.60M | 1.39M | 1.02M | 1.10M |
| Total revenue | 12.82M | 11.72M | 10.93M | 10.31M | 9.29M |
| Total operating expenses | 1.92M | 1.83M | 1.73M | 1.51M | 1.38M |
| Cost of revenue | 0.83M | 0.71M | 0.82M | 0.82M | 0.88M |
| Total other income expense net | 0.10M | 0.00450M | -0.26342M | 0.24M | 0.03M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 8.37M | 7.67M | 6.73M | 7.20M | 5.86M |
| Net income applicable to common shares | - | 7.67M | 6.73M | 7.20M | 5.86M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 13.28M | 13.12M | 12.91M | 13.30M | 11.61M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | - | 5.22M | 4.63M | 3.65M | 3.93M |
| Total liab | 1.22M | 1.30M | 1.09M | 0.78M | 0.79M |
| Total stockholder equity | 12.06M | 11.82M | 11.82M | 12.52M | 10.83M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 1.12M | 1.09M | 1.01M | 0.29M | 0.23M |
| Common stock | 0.26M | 0.26M | 0.26M | 0.26M | 0.26M |
| Capital stock | 0.26M | 0.26M | 0.26M | 0.26M | 0.26M |
| Retained earnings | 10.33M | 10.23M | 10.23M | 10.95M | 10.13M |
| Other liab | - | 0.04M | 0.08M | 0.05M | 0.03M |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | - | - |
| Cash | 5.72M | 6.13M | 6.49M | 8.08M | 6.54M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1.20M | 1.25M | 1.01M | 0.73M | 0.76M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -5.71582M | -6.12665M | -6.49498M | -8.07647M | -6.53732M |
| Short term debt | - | - | - | - | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | - | - | - | - | - |
| Other stockholder equity | 1.47M | -10.48745M | -10.48661M | -11.20737M | 0.44M |
| Property plant equipment | - | 0.69M | 0.84M | 0.72M | 0.51M |
| Total current assets | 12.10M | 11.81M | 11.45M | 11.97M | 10.71M |
| Long term investments | - | - | - | - | 0.39M |
| Net tangible assets | - | 11.82M | 11.82M | 12.52M | 10.83M |
| Short term investments | - | - | - | - | - |
| Net receivables | 1.17M | 0.76M | 4.63M | 0.64M | 0.73M |
| Long term debt | - | - | - | - | - |
| Inventory | 0.57M | 0.46M | 0.33M | 0.25M | 0.24M |
| Accounts payable | 0.08M | 1.25M | 1.01M | 0.73M | 0.76M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | -0.58459M | -0.48549M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.26M | 0.26M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.61M | -1.30441M | -1.45376M | -1.32854M | 0.39M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1.19M | 1.30M | 1.45M | 1.33M | 0.90M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | 0.09M | -0.00695M | -0.22920M | -0.22166M | -0.09695M |
| Change to liabilities | - | 0.08M | 0.06M | 0.13M | 0.03M |
| Total cashflows from investing activities | - | -0.00695M | -0.22920M | -0.52021M | -0.14684M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | -8.30370M | -7.91849M | -7.68959M | -5.62355M | -6.17982M |
| Change to operating activities | - | - | - | - | - |
| Net income | 8.37M | 7.67M | 6.73M | 7.20M | 5.86M |
| Change in cash | -0.41083M | -0.36834M | -1.58148M | 1.54M | -0.44919M |
| Begin period cash flow | 6.13M | 6.49M | 8.08M | 6.54M | 6.99M |
| End period cash flow | 5.72M | 6.13M | 6.49M | 8.08M | 6.54M |
| Total cash from operating activities | 7.80M | 7.56M | 6.34M | 7.68M | 5.88M |
| Issuance of capital stock | 0.14M | 0.00000M | 0.02M | 0.88M | 0.04M |
| Depreciation | 0.13M | 0.14M | 0.14M | 0.13M | 0.07M |
| Other cashflows from investing activities | - | 0.00480M | 0.03M | 0.04M | 0.03M |
| Dividends paid | 8.44M | 7.92M | 7.71M | 6.50M | 6.22M |
| Change to inventory | -0.10355M | -0.12936M | -0.08704M | -0.00613M | 0.04M |
| Change to account receivables | - | -0.59875M | -0.97660M | 0.28M | -0.11712M |
| Sale purchase of stock | - | - | 0.02M | 0.88M | 0.04M |
| Other cashflows from financing activities | 0.09M | -0.00030M | -0.22920M | -0.52021M | -0.14684M |
| Change to netincome | - | 0.39M | 0.47M | -0.06575M | -0.00441M |
| Capital expenditures | 0.01M | 0.01M | 0.26M | 0.34M | 0.08M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -0.78271M | -0.65176M | -1.00412M | 0.41M | -0.04728M |
| Stock based compensation | 0.17M | 0.24M | 0.26M | 0.12M | 0.13M |
| Other non cash items | -0.10109M | -0.00450M | -0.03063M | -0.04107M | -0.03463M |
| Free cash flow | 7.79M | 7.55M | 6.08M | 7.34M | 5.79M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BVXP Bioventix |
-25.0 0.75% | 3300.00 | 27.22 | 25.97 | 18.06 | 18.93 | 17.37 | 21.69 |
| ONT Oxford Nanopore Technologies Ltd |
-4.0 2.80% | 139.10 | - | - | 10.88 | 2.75 | 8.77 | -16.7946 |
| GNS Genus PLC |
-6.0 0.40% | 1508.00 | 42.59 | 25.71 | 2.08 | 2.46 | 2.31 | 16.39 |
| PRTC PureTech Health plc |
2.42 1.57% | 157.02 | - | - | 35.55 | 1.04 | 95.87 | -4.5333 |
| AVCT Avacta Group PLC |
-0.52 1.09% | 46.98 | - | - | 23.19 | 14.78 | 20.75 | -10.4566 |
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, the United Kingdom.
27?28 Eastcastle Street, London, United Kingdom, W1W 8DH
| Name | Title | Year Born |
|---|---|---|
| Mr. Peter John Harrison MA | CEO & Director | 1958 |
| Mr. Bruce Edward Heath Hiscock | CFO & Director | 1958 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...